Abstract： Objective To evaluate the clinical efficacy and toxicity of the regimen of paclitaxel combined with gemcitabine for anthracycine-resistant metastatic breast cancer. Methods Thirty patients with anthracycine-resistant metastatic breast cancer were enrolled in the study: paclitaxel 135mg/m2 infusion on day 1; Gemcitabine 850mg/m2 infusion on day 1,8 ,and administered in three weeks cycle. The clinical efficacy was evaluated every two cycles. Results Of all thirty patients qualified for efficacy analysis and among them CR 3 cases( 10％ ) ,PR 11 cases (36.7 ％ ), SD 11 cases ( 36.7％ ), and PD 5 cases ( 16.7％ ), with an overall response rate of 46.7％. The median TTP and overall survival in those 30 patients was 7.1 and 15.6 months. The main toxicities with grade 3 and 4 were hypoleucocytosis in 10 patients(30.0％ ) ,thrombocytopenia in 4 patients( 13.3％ ). Conclusion The regimen of paclitaxel combined with gemcitabine was effective,well-tolerated scheme in the anthracycine-resistant metastatic breast cancer.